Comparison of the prophylactic antithrombotic effect of indobufen and warfarin in patients with nephrotic syndrome: a randomized controlled trial. Issue 1 (31st December 2023)

• Record Type: Journal Article
• Authors: Gao, Xin-Yi; Liu, Yue-Ming; Zheng, Dan-Na; Li, Yi-Wen; Li, Hua; Xiong, Xiao-Ling; Chen, Hong-Yu; Wang, Hua; Yu, Xiao-Yong; Qu, Kai; Jin, Juan; Lin, Bo; He, Qiang
• Is Part Of: Renal failure. Volume 45:Issue 1(2023)
• Publication Date: 2023-12-31
• Subjects: Antithrombotic effect -- indobufen -- warfarin -- nephrotic syndrome -- randomized controlled trial; Chronic renal failure -- Periodicals; Acute renal failure -- Periodicals; Uremia -- Periodicals; 616.614005
• DOI: 10.1080/0886022X.2022.2163505
• Languages: English
• ISSNs: 0886-022X

Abstract

Abstract: Purpose: The risk of thromboembolic events is elevated in patients with nephrotic syndrome, and warfarin use has been associated with an increased risk of bleeding. Indobufen, a selective cyclooxygenase-1 inhibitor, is currently being evaluated for the prevention of thromboembolic events in nephrotic syndrome. This study aimed to compare the efficacy and safety of indobufen with that of warfarin in patients with nephrotic syndrome. Materials and methods: This multicenter, randomized, three-arm, open-label, parallel controlled trial involved a total of 180 adult patients with nephrotic syndrome from four centers in China. Patients were randomly assigned to receive 100 mg indobufen (bid), 200 mg indobufen (bid), and 3 mg warfarin (qd) daily for 12 weeks. The primary endpoints included thromboembolic and bleeding events, while laboratory results and adverse events constituted secondary endpoints. Results: No thromboembolic events occurred in the high-/low-dose indobufen and warfarin groups. Moreover, the use of a low dose of indobufen significantly reduced the risk of minor bleeding events compared with warfarin use (2% versus 18%, p < .05). Finally, adverse events were more frequent in warfarin-treated patients. Conclusions: This study found that indobufen therapy provided equivalent effects in preventing thromboembolic events compared with warfarin therapy, while low dose of indobufen was associated with a reduced risk of bleeding events, thus it should be recommended for the prevention of thromboembolic events in clinical practice in patients with nephrotic syndrome. Trial registration number: ChiCTR-IPR-17013428.